JUNIPER PHARMACEUTICALS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-10-28: Form 8-K; Period of report 2014-10-28; Description 2.02 Results of Operations and Financial Condition.
- 2014-09-26: Form 8-K; Period of report 2014-09-23; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; Details 5.02.
- 2014-08-06: Form 8-K; Period of report 2014-08-06; Description 8.01 Other Events; Details 8.01.
- 2014-07-31: Form 8-K; Period of report 2014-07-31; Description 2.02 Results of Operations and Financial Condition.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2014-10-28 | 8-K | 2014-10-28 | 2.02 Results of Operations and Financial Condition | d810807d8k.htm | |
| 2014-09-26 | 8-K | 2014-09-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On September 23, 2014, the Board of Directors of Columbia Laboratories, Inc. (the “Company”) appointed George O. Elston as the Company’s new Chief Financial Officer, effective October 1, 2014, to replace Jonathan Lloyd Jones, who is stepping down from the role to pursue other opportunities. 7.01 On September 24, 2014, the Company issued a press release entitled “Columbia Laboratories Announces Appointment of New Chief Financial Officer,” announcing that Mr. Elston will be joining the Company as its new Chief Financial Officer to replace Jonathan Lloyd Jones, who is stepping down from the role to pursue other opportunities. | d795496d8k.htm |
| 2014-08-06 | 8-K | 2014-08-06 | 8.01 Other Events | 8.01 On August 6, 2014, Columbia Laboratories, Inc. (the “Company”) announced that Lil’ Drug Store Products, Inc. (“Lil’ Drug Store”) has exercised its option to purchase the intellectual property rights and technology related to Legatrin P.M. (the “IP Rights”), pursuant to the terms of the License Agreement, dated as of April 18, 2000, by and between the Company and Lil’ Drug Store (the “License Agreement”), for approximately $2.2 million. | d771292d8k.htm |
| 2014-07-31 | 8-K | 2014-07-31 | 2.02 Results of Operations and Financial Condition | d769480d8k.htm | |
| 2014-05-08 | 8-K | 2014-05-08 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 At the 2014 Annual Meeting of Stockholders of Columbia Laboratories, Inc. (the “Company”), held on May 8, 2014, three proposals were submitted to and approved by the stockholders. | d725478d8k.htm |
| 2014-04-29 | 8-K | 2014-04-29 | 2.02 Results of Operations and Financial Condition | d720565d8k.htm | |
| 2014-03-07 | 8-K | 2014-03-06 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 1.02 As described in Item 1.01 of this Current Report on Form 8-K, on March 6, 2014, in conjunction with the Purchase Agreement, the Investor’s Rights Agreement was terminated. 5.02 On March 6, 2014, in connection with the termination of the Investor’s Rights Agreement, Fred Wilkinson, who has served on the Board since July 2010 as Coventry’s Designee under the Investor’s Rights Agreement, resigned from his position as a director of the Company. 7.01 On March 7, 2014, Columbia Laboratories, Inc. (the “Company”) issued a press release entitled “Columbia Laboratories Repurchases 1.4 Million Shares of Common Stock from Actavis”, announcing the repurchase of 1,400,000 shares of common stock of the Company from Coventry Acquisition, LLC, a Delaware limited liability company and a subsidiary of Actavis, Inc. A copy of the press release is furnished and attached as Exhibit 99.1 hereto and is incorporated herein by reference. | d689194d8k.htm |
| 2014-03-05 | 8-K | 2014-03-05 | 2.02 Results of Operations and Financial Condition | d689039d8k.htm | |
| 2014-03-03 | 8-K | 2014-02-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On February 28, 2014, Edward A. Blechschmidt notified the Board of Directors (the “Board”) of Columbia Laboratories, Inc. (the “Company”) that he will not stand for re-election at the Company’s upcoming annual meeting of stockholders. | d687737d8k.htm |
| 2014-02-20 | 8-K | 2014-02-19 | 2.02 Results of Operations and Financial Condition; 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | 2.02 On February 19, 2014, Columbia Laboratories, Inc. (the “Company”) issued a press release announcing that it will restate its previously issued unaudited interim consolidated financial statements for the three and nine months ended September 30, 2013. 4.02 On February 19, 2014, the Company, in consultation with the Company’s independent registered public accounting firm and the audit committee of the Company’s board of directors, determined that its previously issued unaudited interim consolidated financial statements for the three- and nine-month periods ended September 30, 2013 should no longer be relied upon due to a calculation error related to the Company’s common stock warrant expense, which resulted in the overstatement of the Company’s common stock warrant expense for the three- and nine-month periods ended September 30, 2013, and affects, among other things, the Company’s reported net (loss) income and net (loss) income per common share (basic and diluted). | d678508d8k.htm |
| 2014-02-06 | 8-K | 2014-02-05 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d672685d8k.htm |
| 2014-01-09 | 8-K | 2014-01-09 | 2.02 Results of Operations and Financial Condition | 2.02 On January 9, 2014, Columbia Laboratories, Inc. (the “Company”) issued a press release providing preliminary financial results for the fiscal quarter and fiscal year ended December 31, 2013, entitled “Columbia Laboratories Announces Preliminary Fourth Quarter and Year-End 2013 Results” (the “Press Release”). | d657050d8k.htm |